Excellent Survival After Stem Cell Transplantation for non-SCID Primary Immunodeficiencies  by Martinez, C.A. et al.
S184 Oral PresentationsTable 1. Summary of 21 SCT patients with BK viremia
High Viremia: Low Viremia:
>10,000
copies/ml
(n510)#10,000
copies/ml
(n511)p
valueUrine BK >1 billion copies/ml 8 (80%) 8/10 (80%) p>0.99**
Obstructive uropathy
requiring surgical interventions
5 (50%) 0 (0%) p50.01*Average maximum fold increase in
creatinine from pre-SCT6.4 2.1 p50.02***Renal replacement therapy 6 (60%) 1 (9%)# p50.02*
Biopsy proven polyoma
virus-associated nephropathy
3/3 samples none doneEnd stage renal disease 5 (50%) 0 (0%) p50.01*
Mortality attributed to BK virus 3 (30%) 0 (0%) p50.09*# Not attributed to polyoma virus-associated nephropathy.
*Fisher’s exact test.
**Unconditional exact test.
***Wilcoxon Two-Sample Test.82
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN INFANTS
Leucht, S., Ashraf, K., Schechter, T., Doyle, J., Gassas, A. Hospital for Sick
Children, University of Toronto, Toronto, ON, Canada
Introduction: It is rare for an infant (less than 1 year old) to receive
HSCT and little is known about indications and outcomes in this
high risk population. Our objective herein was to review the indica-
tions and outcomes for all infants who received HSCT in a large
pediatric transplant centre.
Methods: A retrospective analysis of all children who receivedHSCT
was performed. Infants with an underlying immunological disorder
such as severe combined immune deficiency (SCID) were excluded.
Results: Between April 1992 and March 2010, 1363 (allogeneic 775,
autologous 588) children received HSCT in the Hospital for Sick
Children in Toronto. Fifty-one (3.7%) were infants. Seventeen infants
received allogeneic HSCT for an underlying metabolic disorder (os-
teopetrosis 7, Hurler syndrome 7, GM gangliosidosis 1, Niemann-
Pick type A 1 and Krabbes disease 1). The median age of diagnosis
was 78 days (antenatal-248 days). The median age at HSCT was 207
days (29-334 days). They all received myeloablative regimens. For
a median follow-up of 7.1 yrs (0.9-18.4 yrs) 13 patients are alive with
an overall survival in this group of 76%. Causes of death were TRM
in 3 and 1 patient (Niemann-Pick type A) died 4 ½ yrs post HSCT
from progressive disease despite full donor engraftment.
The remaining 34 infants, 10 received autologousHSCT (NBL 3,
AML 2, Brain tumor 3, Rhabdomyosarcoma 1, Retinoblastoma 1).
Twenty-four infants received allogeneic HSCT (13 related, 11 unre-
lated)- HLH 8, JMML 4, WAS 4, ALL 3, AML 2, SAA 1, CGD 1
and Amegakaryocytic Thrombocytopenia 1.Median age at diagnosis
was 103 days (1-200 days), median age at HSCT was 254 days (142-
365 days). All patients receivedmyeloablative regimens. For amedian
follow-up of 6.7 yrs (0.5-15.6 yrs) 25 infants are alive with an overall
survival in this group of 73%. Nine infants (27%) died, 6 due to
TRM and 3 because of disease relapse.
Eight out of ten infants who received autologous HSCT are long
term survivors.
Early post HSCT complications for all patients were mainly related
to feeding issues requiring long termNG/GT feeding. In terms of de-
velopmental and long term outcomes, the majority were delayed in
their developmental milestones at 12 months of age. However, most
of them caught up later on and attained good performance scales.
Conclusion: Our results for HSCT in infants are very encouraging
with good long term developmental mile stones and excellent
functional long term survival.83
STEM CELL TRANSPLANTATION FOR CD3-DELTA DEFICIENCY
Marcus, N.1, Takada, H.2, Dalal, J.3, Regueiro, J.R.4, Friedrich, W.5,
Roifman, C.1 1University of Toronto & Affiliated Hospitals, Toronto,ON, Canada; 2Kyushu University, Fukuoka, Japan; 3University of Mis-
souri-Kansas City School of Medicine, Kansas City, MO; 4Universidad
Complutense, Madrid, Spain; 5Universit€atskinderklinik, Ulm, Germany
Rational:CD3-delta deficiency is a rare fatal form of SCID which is
potentially cured by hematopoetic stem cell transplantation
(HSCT). Being a rare disease optimal transplantation protocols for
this group of patients has not been established.
Methods: We retrospectively analyzed the data on 9 patients with
CD3-delta deficiency from 5 centers in Japan North America and
Europe that underwent HSCT, using different sources of donor
stem cells and different conditioning regimens.
Results:Mean age at HSCT was 5 months. 3 patients received stem
cells from a matched unrelated donor (MUD), with myeloablative
conditioning. They are alive and well. All of them experienced rapid
engraftment and full immune reconstitution. One of these patients
has recently delivered a healthy baby girl, 18y post BMT. 2 patients
received a matched cord transplant without conditioning. One of
them has had a partial but stable engraftment, while the other en-
grafted well but has only been followed for 12 months after
HSCT. Two other patients received a mismatched related donor
(MMRD). Both theses patients had failed to engraft and finally
died. Another 2 patients received stem cells from a matched related
donor (MRD), one with reduced conditioning regimen. This patient
lost his graft and recently underwent a second BMT. The other pa-
tient who received full conditioning is doing well and achieved full
immune reconstitution as well.
Conclusions: HSCT from MUD was successful. Myeloablative
conditioning may be necessary for engraftment of bone marrow de-
rived stem cells in these patients. It’s interesting to speculate that
cord stem cells may override that need.84
EXCELLENT SURVIVAL AFTER STEM CELL TRANSPLANTATION FOR NON-
SCID PRIMARY IMMUNODEFICIENCIES
Martinez, C.A.1, Hanson, I.C.2, Rosenblatt, H.M.3, Chinen, J.2,
Leung, K.1, Kennedy-Nasser, A.1, Craddock, J.1, Brenner, M.1,
Heslop, H.1, Chokshi, N.4, Shearer, W.2, Krance, R.1 1Texas Children’s
Cancer Center, Baylor College of Medicine, Houston, TX; 2Texas Child-
ren’s Hospital, Baylor College of Medicine, Houston, TX; 3Dell Children’s
Medical Center of Central Texas, Austin, TX; 4Texas Children’s Hospital,
Baylor College of Medicine, Houston, TX
Allogeneic hematopoietic stem cell transplantation (HSCT) for
patients with Primary Immunodeficiencies (PIDs) has provided
a life saving therapy. There is less information available regarding
the utilization of stem cell transplantation for children with PIDs
other than SCID. We report the outcome following HSCT (1998-
2010) in 31 non-SCID patients: WAS (n 5 6), CGD (n 5 12),
LAD (n 5 3); and other T cell defects (n 5 10). The T cell defects
group included patients with NK cell defects (n5 2), X-linked lym-
phoproliferative disease (n5 2), NEMO (n5 1), HLA-class II defi-
ciency (n 5 1), Hyper IgM syndrome (n 5 1), DiGeorge Anomaly
(n 5 2) and Zap 70 deficiency (n 5 1). The patient median age at
transplant was 2.5 years (range, 0.3-16 years). Fourteen patients
received a matched related donor graft (MRD), thirteen patients re-
ceived a matched unrelated donor graft (MUD), two patients re-
ceived a mismatched unrelated donor graft and two patients
received a mismatched unrelated cord blood unit. Most patients (n
5 25) received a myeloblative conditioning consisting of busulfan,
cyclophosphamide, and fludarabine or cytarabine. Two patients re-
ceived total body radiation at 1400Gy. Only four patients received
a sub-myeloablative conditioning with cyclophosphamide and bu-
sulfan backbone with or without fludarabine. Two patients with
complete DiGeorge Syndrome were not conditioned. Graft vs host
disease (GvHD) prophylaxis usually combined cyclosporine and
metrotrexate or cyclosporine and prednisone.Most patients received
Campath to improve engraftment and to prevent GvHD. The me-
dian time for neutrophil recovery was 18 days (range, 12-37 days).
Twenty four patients achieved full donor chimerism (donor chime-
rism . 95%) and seven patients achieved mixed donor chimerism
(mean: 70%, range, 40-90%) but with correction of defective im-
mune function. There was no incidence of graft failure. Eight pa-
tients developed grade I aGvHD requiring only topical treatment.
Only one patient developed grade II-IV aGvHD. Chronic GvHD
Oral Presentations S185was observed in one patient. The overall survival of these patients
was 94% with a median follow up of 2.8 years (range, 0.2-12 years).
The causes of death were infection and complications of aGVHD.
These results demonstrate the usefulness of using HSCT in the
non-SCID population and absence of an MRD should not delay
HSCT. We conclude that HSCT should be considered early and
prior to the onset of significant morbidity in non-SCID PIDs.85
IMPROVED CLINICAL OUTCOME OF HIGH RISK b THALASSEMIA MAJOR
PATIENTS UNDER GOING A HLA MATCHED RELATED ALLOGENEIC
STEM CELL TRANSPLANT WITH THE USE OF A TREOSULPHAN BASED
CONDITIONING REGIMEN
Mathews, V., George, B., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., Srivastava, A. Christian Medical College, Vellore,
Tamil Nadu, India
The clinical outcome post allogeneic SCT in patients with b thal-
assemia major (TM) who belong to the Class III and the Class III
high risk group (defined by us previously; BBMT 2007;13:889),
remains poor.
From August 2009 we used a Treosulphan based conditioning
regimen (thiotepa: 8 mg/kg on day-6, treosulphan: 14gm/m2 for 3
days from day -5 to -3 and fludarabine 40mg/m2 for 4 days from
day -5 to -2) in an effort to improve the clinical outcome in these sub-
sets. 18 patients have since then had this conditioning regimen at our
center. The median age was 10 years (range: 2 – 17) and the median
liver size was 6 cm (range: 2-10). 15 (83.3%) were Class III while 10
(55%) wereClass III high risk (age$ 7 years and liver size$ 5cms). 3
were HCV positive, 2 were having a second SCT and 4 patients had
a prior splenectomy. All patients had HLA identical related donors.
Bone marrow was the source of stem cells in 14 (77%) while the rest
had PBSC. Themedian TNCdose was 3.95x108/kg (range: 2.5-8.4).
All 18 patients engrafted (ANC . 500/mm3) at a median of 17 days
(range: 11 – 22). Features suggestive of a SOSwere seen in 4 patients,
of whom 2 subsequently died on day 41 and 44 respectively (second-
ary to sepsis and multi-organ failure). In 7 patients there was tran-
sient hypoxia, the etiology of which could not be explained by
routine tests and imaging. DAH occurred in 4 of these cases and 2
of them (who also had features of SOS) succumbed to subsequent
complications. Besides the two deaths an additional patient has had
secondary graft failure on day 76 (with autologous recovery). Of
the remaining 15 patients a day 28 chimerism (VNTR assay) study
revealed complete chimerism in 10 (66%) while 4 had donor chime-
rism over 90% and over the next fewmonths improved further (none
require blood transfusions). 4 (27%) of the 15 patient who could be
evaluated developed acute GVHD which was grade III/IV in one
case. In comparison to our previously reported data among the entire
Class III and the Class III high risk subset who had an EFS of
70.366% and 2467% respectively (BBMT 2007), these results are
a significant improvement.
In conclusion a treosulphan based conditioning regimen is well
tolerated in high risk patients with TM. While the incidence of
SOS is very low compared to that seen with a conventional busul-
phan based regimen there remains some concern about the high in-
cidence of pulmonary complications that was noted in this cohort.86
RISK STRATIFICATION WITHOUT A LIVER BIOPSY OF PATIENTS WITH
b THALASSEMIA MAJOR UNDER GOING A MATCHED RELATED ALLOGE-
NEIC BONE MARROW TRANSPLANT
Mathews, V., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., George, B., Srivastava, A. Christian Medical College,
Vellore, TN, India
Conventional risk stratification of patients with b thalassemia ma-
jor (TM) prior to an allogeneic SCT requires a liver biopsy. 288 pa-
tients with TM underwent a SCT at our center. The median age was
7 years (range: 2-24). By the conventional risk stratification, 14
(4.9%)wereClass I while 142 (49.3%)wereClass III.Myelo-ablative
conditioning regimen in the majority was busulphan based (oral).
284 (98.6%) received a bone marrow graft. At a median follow up
of 49 months (range: 2-213) the 5 year Kaplan-Meir estimate ofoverall survival (OS) and event free survival (EFS) was 71.362.8%
and 64.762.9% respectively. On a univariate analysis factors associ-
ated with an adverse impact on EFS were patients’ age, donor age,
liver size, serum AST level, serum ferritin level, palpable spleen
and splenectomy. On a multivariate analysis only liver size retained
its significant adverse impact. Since the majority of our patients be-
longed to Class III and we had earlier shown that age $ 7 years and
liver size$ 5 cms had a significant adverse impact in this group, even
on a multivariate analysis (BBMT 2007) we used these numbers to
dichotomize the group. Of the remaining factors that had an adverse
impact on EFS, donor age (significant correlation with recipient age)
and splenectomy (small number) were excluded. The median values
of the serumAST ($ 50U/Lt) and ferritin ($ 3000mg/Lt) levels were
then also used to dichotomise the group. On a cox-regression anal-
ysis liver size $ 5cms (RR 5 2.8; P 5 0.000), age $ 7 years (RR 5
2; P 5 0.004), serum ferritin $ 3000mg/Lt (RR 5 1.6; P 5 0.029)
and a palpable spleen (included those that had splenectomy) (RR
5 2.2; P 5 0.004) were significant. Scores were generated for each
of the above adverse factors proportional to the relative risk as illus-
trated in Table 1. The total score could therefore range form 0 to 9
for each patient. Kaplan-Meir estimates of EFS were generated for
each of these scores and clustered into groups. Three groups could
be recognized; Group A with a score # 2 (n 5 121 [42%]), Group
B 5 . 2 to \ 9 (n 5 118 [41%]) and Group C 5 9 (n 5 48
[17%]). Kaplan-Meir estimates of EFS and cumulative risk of rejec-
tion between these groups was significantly different (P5 0.000 and
0.007 respectively)
The proposed risk stratification does not require a liver biopsy, has
a good distribution of cases in the defined groups and better
identifies a high risk subset of patients than the conventional risk
stratification system.
Table 1. Scoring systemVariable/Score 0 2 3
Liver Size (cm) <5 $ 5
Age (years) <7 $ 7
Serum Ferrtin (mg/Lt) <3000 $ 3000
Spleen palpable No Yes/Post splenectomy87
DIFFERENTIAL IMPACT OF HLA-A, -B, AND -DRB1 MISMATCHING IN RE-
LATION TO OTHER VARIABLES ON THE OUTCOMES OF MYELOABLATIVE
UNRELATED SINGLE DONOR UMBILICAL CORD BLOOD TRANSPLANTA-
TION FROM 4/6 MATCHED UNITS IN CHILDREN AND YOUNG ADULTS
Prasad, V.K.1, Mendizabal, A.2, Tewari, P.1, Page, K.1, Parikh, S.H.1,
Szabolcs, P.1, Driscoll, T.A.1, Martin, P.L.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2The EMMES Corporation,
Rockville, MD
Background: Use of 4/6 matched cord blood units (CBU) substan-
tially expands the chances of finding a suitable donor for patients
lacking an adult match. An understanding of the impact of locus-spe-
cific HLA mismatching, cellular characteristics of CBU and other
variables will help optimize CBU selection and further improve out-
comes of 4/6 unrelated cord blood transplant (UCBT).
Methods: All recipients (age # 21yrs) of myeloablative UCBT be-
tween 08/1993 and 11/2007 at Duke from single 4/6 matched
(low-res HLA-A and B; high-res DRB1) CBU were studied (median
follow-up 6.9 years; range, 0.9-15.1). Of 314 patients (median age 6.1
years; range 0.1-20.3), 63% were male, 27% non-Caucasian, 38%
CMV positive, and 61% transplated for malignancy. Statistics in-
cluded Kaplan-Meier (KM), log-rank, and Cox models. Prognostic
factors were assessed in univariate KM analyses of overall survival
(OS) and cumulative incidence (C_Inc) of engraftment and
GVHD. Cox proportional hazards models were constructed using
stepwise selection. P-values\ 0.05 were statistically significant in
multivariate model. Median (range)/kg of cryopreserved TNC, rein-
fused TNC, CD34, and CFU doses were 6.2(0.9-38.2)x107, 4.8(0.5-
27.4)x107, 1.8(0.02-105)x105, and 3.6(0-50)x104, respectively.
RESULTS: Primary graft failure and autologous recovery occurred
in 21 (6.7%) and 10 (3.2%). C_Inc of grades III-IV acuteGVHDand
chronic GVHD at 1 year was 13.6%(95%CI, 9.8%-17.4%) and
13.9%(95%CI, 9.9%-17.9%). OS at 1 year and 3 years were
54.8%(95%CI, 49.1%-60.1%) and 47.5%(95%CI, 41.8%-52.9%),
